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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.008To study the effect of themicronutrient seleniumonmalignantmesothelioma (MM) progression, we cultured
four different MM cell lines in media containing increasing amounts of sodium selenite (30, 50, and 80
nmol/L). Increasing selenium levels increased density-dependent proliferation and mobility for CRH5 and
EKKH5 but not AB12 and AK7. Comparing these cell lines revealed that extracellular regulated kinase (ERK)
phosphorylation was sensitive to a selenium increase in CRH5 and EKKH5 but not AB12 and AK7 cells. Stable
expression of a dominant-negativemutant ERK eliminated the effects of increasing selenium. Because ERK is
redox sensitive, we compared the MM cell lines in terms of glutathione levels and the capacity to reduce
exogenous hydrogen peroxide. Increasing selenium levels led to higher glutathione and reducing capacity in
CRH5 and EKKH5 but not AB12 and AK7. The reducing agent N-acetylcysteine eliminated the effects of se-
leniumon ERK activation, proliferation, andmobility. Mice fed diets containing increasing levels of selenium
(0.08, 0.25, and 1.0 ppm) showed increased tumor progression for CRH5 but not AB12, MM cells, and in vivo
N-acetylcysteine treatment eliminated these effects. These data suggest that the effects of dietary selenium
on MM tumor progression depend on the arising cancer cells’ redox metabolism, and the tumors able to
convert increased selenium into a stronger reducing capacity actually beneﬁt from increased selenium
intake. (Am J Pathol 2014, 184: 1041e1049; http://dx.doi.org/10.1016/j.ajpath.2013.12.008)Funded by NIH grant R01AI089999 (P.R.H.), the Hawaii Community
Foundation (P.R.H. and P.B.), and the Buzzi UNICEM Foundation award
FBU-P31 (P.B.).
Disclosures: None declared.Dietary selenium is an essential micronutrient that is impor-
tant for many aspects of human health.1 The biological effects
of selenium are exerted mainly through the actions of the
proteins into which it is incorporated (ie, selenoproteins).2
The human genome contains 25 genes that encode for sele-
noproteins and several of these are enzymes that play
important roles in regulating cellular redox status.3,4 Within
cells, dietary selenium also may be metabolized into inter-
mediate compounds such as methylselenol, which affect
redox homeostasis and may exert toxic effects on cancer
cells.5,6 An abundance of preclinical ﬁndings together with
some clinical data have suggested that selenium supplemen-
tation may prove to be an affordable, effective means to
prevent or treat a wide variety of cancers.7,8 However, the
effectiveness of selenium supplementation for cancer pre-
vention has been inconsistent and somewhat controver-
sial.9e11 These inconsistencies may be owing to differences
in the form of selenium supplementation used, to the baselinestigative Pathology.
.selenium status of the participants in different populations, or
to other study design factors.12 In addition, certain seleno-
proteins have been shown to actually promote tumor pro-
gression,13,14 which highlights the importance of identifying
the molecular mechanisms by which dietary selenium in-
ﬂuences the development of each type of cancer.
Malignant mesothelioma (MM) is a deadly cancer associ-
ated with asbestos or erionite exposure for which no suc-
cessful therapies are currently available. MM is among the
most aggressive tumors, arising from the mesothelial cells
that line the pleura, peritoneum, and, occasionally, the peri-
cardium.15 Dietary selenium has been proposed to play a
potential chemopreventive role in the prevention or treatment
Rose et alofMM, although the data are limited. In one study involving a
MM cell line, selenium was shown to inhibit MM cell growth
and induce apoptosis in a dose-dependent manner.16 How-
ever, the levels of selenium required for these effects were
extremely high, and other in vivo studies involving selenium
and vitamins A and E did not show beneﬁcial effects of any of
these dietary antioxidants on tumor development.17 Deter-
mining how selenium status affects MM tumor development
and progression is essential given that MM incidence is
increasing in the United States and other parts of the world,18
and selenium intake varies in different geographic regions,
with selenium supplementation considered as a potential
treatment approach for MM and other cancers.
An emerging perspective of the role that seleniummay play
in chemoprevention has focused on the different stages of
tumor development: the initial carcinogenesis events
involving DNA repair in which increased selenium may be
beneﬁcial, and the subsequent progression of established tu-
mors for which the effects of increasing selenium intake may
vary.19 To address the issue more speciﬁcally of whether
different levels of selenium intake inﬂuence the progression
of MM tumors after they have been established, we used
several different MM cell lines generated by the administra-
tion of asbestos particles into mice and investigated the
impact of dietary selenium levels on tumor progression.
Surprisingly, we found that increasing selenium intake did
not limit the growth of any of the cell lines and higher sele-
nium levels actually promoted proliferation, mobility, and
in vivo tumor progression for someMM cell lines. We further
identiﬁedmolecular mechanisms that were affected by higher
selenium intake involving redox-sensitive signaling path-
ways converging at the point of extracellular regulated kinase
(ERK) phosphorylation. Overall, the data presented herein
provide crucial insight into the mechanisms by which dietary
selenium affects MM tumor progression and suggest that the
use of selenium supplementation to treat MM may in some
cases be more harmful to the patients.
Materials and Methods
Mice, Cell Lines, and Reagents
C57BL/6 and Balb/c mice originally obtained from Jackson
Laboratories (BarHarbor,ME)were used to generate colonies.
Male weanling mice were maintained on diets containing
different levels of selenium (0.08, 0.25, or 1.0 ppm selenium)
for a minimum of 4 weeks to effectively establish selenium
status as previously described.20 At 8 to 10weeks of age, mice
were used for experiments, and all animal protocols were
approved by the University of Hawaii Institutional Animal
Care and Use Committee. The MM cell lines AB12, AK7,
CRH5, and EKKH5 were generated as previously de-
scribed,21e23 and cultured in F-12 media with 10% fetal
bovine serum (GIBCO/Invitrogen, Grand Island, NY). The
selenium content of the fetal bovine serum was determined by
IC-MS (West Coast Analytical Service, Santa Fe Springs,1042CA), and increasing levels of seleniumwere established in the
culturemedia by addition of sodium selenite (Sigma, Chicago,
IL) to the complete F-12 media at a ﬁnal concentration of
30 nmol/L, 50 nmol/L, and 80 nmol/L. Cells were maintained
under these conditions for 1 week before experimentation to
establish selenium status. The reducing agentN-acetylcysteine
(NAC) was purchased from Sigma-Aldrich (St. Louis, MO).
GPx Activity and GSH Assays
After cells were cultured for at least 1 week in low (30 nmol/
L), medium (50 nmol/L), or high (80 nmol/L) levels of se-
lenium, cell pellets were collected, cells were lysed, and
glutathione peroxidase (GPx) activity was analyzed using a
Bioxytech GPx-340 Colorimetric Assay Kit (Oxis Research,
Foster City, CA). Total protein content was measured using a
Bradford Assay (Bio-Rad, Hercules, CA). GPx activity was
normalized to total protein concentration for each sample. For
glutathione (GSH) measurement, cell pellets were harvested
in a similar manner and GSH levels were measured using a
Bioxytech GSH-400 (Oxis Research) and normalized to
protein concentration.
Cell Proliferation and Mobility Assays
After 1 week of maintenance in media with low (30 nmol/L),
medium (50 nmol/L), or high (80 nmol/L) levels of selenium,
cell lines were plated at a density of 103 cells/well in a 96-
well plate in 200 mL fresh media. Media were replaced
every 24 hours to prevent selenium depletion. Every 24 hours
cells were lysed and quantiﬁed using Cyquant Fluorescent
Dye (Invitrogen) and ﬂuorescence detection on a Molecular
Devices Spectramax M3 (Sunnyvale, CA). After reaching
100% conﬂuency the Cyquant Fluorescent Dye would not
accurately bind to target DNA, which led to extremely high
and ﬂuctuating ﬂuorescence readings. Thus, both AK7 and
AB12 reached conﬂuency at day 6, EKKH5 at day 7, and
CRH5 at day 8, and Cyquant dye incorporation was
measured up until those points. After cells were cultured for 1
week in low (30 nmol/L), medium (50 nmol/L), or high (80
nmol/L) levels of selenium, 106 cells/well were plated in 6-
well plates for 24 hours before performing the scratch
assay. A 200-mL pipette tip was used to create four vertical
scratches in the adherent monolayer. The cells were washed
with PBS and then covered with 2 mL of low, medium, or
high selenium media. A Zeiss Axioscope (Oberkochen,
Germany) with a mounted camera was used to capture im-
ages for 10 ﬁelds from each cell line in each condition at
0 and 6 hours after scratch. The images then were analyzed
using ImageJ software version 1.42 (NIH, Bethesda, MD) to
compare the change in area of the scratch at each point.24
Western Blots and Real-Time PCR
Cell pellets were harvested and lysed in CellLytic MT buffer
(Millipore, Billerica, MA) using a probe sonicator. In theajp.amjpathol.org - The American Journal of Pathology
Figure 1 Increasing selenium levels increases the proliferation of
select MM cell lines. Cellular GPx activity increases with increasing selenium
levels [low (30 nmol/L), medium (50 nmol/L), and high (80 nmol/L)] in all
MM cell lines (AK7, AB12, EKKH5, and CRH5). A: A total of 103 cells/well
were plated and allowed to grow to conﬂuency with media changes daily.
B: Proliferation of AK7 and AB12 cells was not affected by selenium levels,
whereas CRH5 and EKKH5 cells showed an increase in proliferation with
increasing levels of selenium during the late stages of growth. Data
represent means  SEM. N Z 3. Means of each selenium group were
compared at each time point. Each experiment was repeated at least twice.
*P < 0.05. MFI, mean ﬂuorescence intensity.
Selenium and Mesothelioma Progressioncase of measuring phosphorylated AKT (pAKT) and
phosphorylated ERK (pERK), cells were cultured in 0.2%
fetal bovine serum media for 24 hours before protein
isolation. Protein concentration in the lysates was measured
by a Bradford assay reagent (Bio-Rad) and 15 mg total
protein was combined with reduced Laemmli buffer, boiled
at 95C for 10 minutes, cooled on ice, and loaded into wells
of 10% to 14.5% polyacrylamide gels (Bio-Rad). After gel
electrophoresis, protein was transferred to polyvinylidene
diﬂuoride membranes, which were blocked for 1 hour with
low ﬂuorescence blocking agent (Li-Cor, Lincoln, NE) and
incubated with primary antibodies including anti-pAKT,
anti-total AKT, anti-pERK, anti-total ERK (Cell Signaling,
Inc., Danvers, MA), anti-GPx1 (Lab Frontier, Inc., Seoul,
Republic of Korea), or antieb-actin (Li-Cor). After washing
with PBS, membranes were incubated with secondary anti-
bodies from Li-Cor for 1 hour, membranes were washed with
PBS, and signals were detected with densitometry conducted
using the Li-Cor Odyssey imaging system. Real-time PCR
was performed as previously described25 using the following
primers: c-fos forward 50-CTCCCGTGGTCACCTGTACT-30,
c-fos reverse 50-TTGCCTTCTCTGACTGCTCA-30, actin
forward 50-TGACAGGATGCAGAAGGAGA-30, and actin
reverse 50-CGCTCAGGAGGAGCAATG-30.
Subcutaneous Tumor Growth
Weanlingmice were fed low (0.08 ppm), medium (0.25 ppm),
and high (1.0 ppm) selenium diets for 4 weeks. These mice
thenwere injected s.c.with 106AB12 orCRH5MMcells. The
mice were monitored for 6 to 7 weeks and tumor volume was
measured using digital calipers as previously described.21 The
mice were sacriﬁced when tumors reached volumes that
threatened the health of the mice (volume, >1500 mm3).
Stable Transfection
The CRH5 and EKKH5 cell lines were transfected with a
plasmid encoding the dominant-negative form of ERK
(TAYE-ERK; a kind gift of Dr. James Turkson, University of
Hawaii Cancer Center) and Lipofectamine reagent (Invi-
trogen). Stably transfected cells were selected by culturing
cells in media containing G418 (Sigma). A killing curve of
100 to 1000 mg/mL showed that 300 mg/mL was the optimal
dosage for selection; G418 was removed after the TAYE-
ERK CRH5 and EKKH5 cell lines were established.
Statistical Analysis
GraphPad Prism software version 4.0 (GraphPad, La Jolla,
CA) was used to compare means in experiments with two
groups using the Student’s t-test. In assays involving three
groups of selenium levels, a one-way analysis of variance
was used to determine the effect of selenium on outcomes,
using the Tukey post-test to compare means of selenium in
groups. For the proliferation assays involving selenium
levels and time, a two-way analysis of variance was used
to test the main effects of selenium and time on outcomes.The American Journal of Pathology - ajp.amjpathol.orgIn addition, interactions between selenium and time on
proliferation were analyzed. The Bonferroni post hoc test
was used to identify the means of different selenium groups
that differed. Standard curves and regression analyses also
were conducted using GraphPad Prism software version 4.0.
All comparisons were considered signiﬁcant at a P value
less than 0.05.
Results
Certain MM Cell Lines Derive a Proliferative and
Migratory Advantage from Increasing Selenium
Concentration
MM cell lines AB12, AK7, CRH5, and EKKH5 were
cultured in media containing increasing levels of selenium.1043
Figure 2 Increasing selenium levels affect the mobility of CRH5 and EKKH5 MM cell lines similar to proliferation. Four different MM cell lines were cultured
in media containing 30, 50, and 80 nmol/L selenium for 1 week, cells were replated, and allowed to grow to conﬂuency. Each experiment was repeated twice.
Images from the scratch assays captured at 0 and 6 hours show mobility. A: Representative images at 6 hours are shown. B: Quantiﬁcation of the scratch
volume was calculated by ImageJ software. Data represent means  SEM. *P < 0.05.
Rose et alActivity of the selenoenzyme, GPx, was measured to
conﬁrm the biological effects of increasing selenium in the
media, and the effects of increasing selenium on prolifera-
tion then was evaluated (Figure 1A). Although all cell lines
equivalently used the bioavailable selenium for increasing
GPx activity, the effect of selenium levels on proliferation
differed among cell lines (Figure 1B). The MM cell lines
CRH5 and EKKH5 showed two stages of growth charac-
terized by an early selenium-independent phase and as the
cells approached conﬂuency they showed higher prolifera-
tion with increasing selenium concentration. In contrast,
proliferation of AK7 and AB12 cell lines were not inﬂu-
enced by increasing selenium levels. We next evaluated the
MM cell lines for the effects of selenium levels on another
important tumor cell function, mobility, using a standard1044scratch assay (Figure 2). Similar to the proliferation data,
CRH5 and EKKH5 showed increased mobility with
increasing selenium whereas the mobility of the AK7 and
AB12 cell lines were not affected by increasing selenium.
ERK Phosphorylation Increases with Increasing
Selenium in the CRH5 and EKKH5 MM Cell Lines
To investigate signaling pathways affected in the selenium-
sensitive versus selenium-insensitive MM cell lines, we
evaluated two important pro-growth signaling molecules
associated with proliferation and mobility in mesothelioma:
ERK and AKT.26e28 CRH5 and EKKH5 cells that respon-
ded to higher levels of selenium with increased proliferation
and mobility also were shown by Western blot analyses toajp.amjpathol.org - The American Journal of Pathology
Figure 3 The effects of selenium on the proliferation and mobility of MM cell lines are mediated by ERK activation. A: Western blot analysis on cell lysates
from 1-week-old cells show an increase in pERK levels with increasing selenium [low (30 nmol/L), medium (50 nmol/L), and high (80 nmol/L)] in CRH5 and
EKKH5, but not AK7 and AB12, cell lines. CRH5 also showed a slight increase in pAKT with increasing selenium. Total ERK and AKT levels were equivalent, as
was b-actin (loading control). Levels of GPx1 conﬁrmed equivalent use of bioavailable selenium for each MM cell line. Data are representative of two in-
dependent experiments. C-fos mRNA levels (B and E), mean ﬂuorescence intensity (MFI) (C and F), and scratch area (D and G) in CRH5 and EKKH5 cells are
shown. The cells were stably transfected with a plasmid encoding a dominant-negative form of ERK (TAYE-ERK). Levels of c-fos mRNA were compared with
housekeeping b-actin mRNA for each sample using real-time PCR. The TAYE-ERK CRH5 and TAYE-ERK EKKH5 cells were cultured in media containing 30, 50, and
80 nmol/L sodium selenite for 1 week and the mobility and proliferation were evaluated. Each experiment was repeated twice. Data represent means  SEM.
*P < 0.05.
Selenium and Mesothelioma Progressionhave increased pERK with increasing selenium (Figure 3A).
The cell lines that did not functionally beneﬁt from
increased selenium uptake, AK7 and AB12, did not show
changes in pERK with increasing selenium. Only CRH5
cells showed slightly increased pAKT with increasing se-
lenium levels, whereas selenium levels did not affect pAKT
in the other cell lines. Because the effects of increasing
selenium on proliferation and mobility shown earlier
correlated most consistently and clearly with ERK activa-
tion, we next generated CRH5 and EKKH5 cell lines stably
expressing the ERK dominant-negative TAYE (CRH5-
TAYE and EKKH5 TAYE). The effects of expressing the
dominant-negative ERK in the CRH5-TAYE and EKKH5
TAYE cell lines were conﬁrmed because these cells showed
about 40% and 15% lower levels of mRNA, respectively,
for the pERK target gene, cFos (Figure 3, B and E). Unlike
the CRH5 and EKKH5 cell lines, the CRH5-TAYE and
EKKH5-TAYE cell lines showed no differences in either
proliferation (Figure 3, C and F) or mobility (Figure 3, D
and G) in response to increased selenium. Overall, theseThe American Journal of Pathology - ajp.amjpathol.orgdata suggest that ERK activation represents an important
signaling event in mediating the effects of increasing sele-
nium in those MM cells that are responsive to changes in
levels of this micronutrient.
Selenium Affects Certain MM Cells by Increasing
Reducing Capacity
Because the phosphorylation of ERK has in some cases
been shown to be a redox-sensitive event, we next investi-
gated the role of redox status in the effects of increasing
selenium on MM cell growth and proliferation. CRH5 and
EKKH5 cells showed increasing levels of reduced GSH
with increasing selenium levels, whereas AB12 and AK7
did not (Figure 4A). To determine if the reducing equiva-
lents of GSH were used differently by the selenium-
sensitive and selenium-insensitive cells, 250 mmol/L H2O2
was added and reactive oxygen species (ROS) levels were
evaluated using dihydrochloroﬂuorescein. Results showed
that increasing selenium levels decreased ROS levels in1045
Figure 4 Reducing capacity with increasing selenium is a crucial mechanism by which proliferation and mobility are affected in selenium-sensitive cells. Cellular
GSH (A), ROS levels (B), and Western blot analysis (C) in MM cell lines cultured in media containing low (30 nmol/L), medium (50 nmol/L), and high (80 nmol/L)
selenium for 1week. For ROS levels thecellswere challengedwith250mmol/LH2O2. ForWesternblot analysis 0.4mmol/LNACwasaddedas a reducingagent for 14hours
before protein extraction andWestern blot analysis. No differences were found in pERK or pAKT for any of the cell lines, and levels of GPx1 conﬁrmed equivalent use of
bioavailable selenium for each MM cell line. Data are representative of two independent experiments. All four MM cell lines cultured in increasing selenium with NAC
added as described earlier showed no differences in proliferation (D) or mobility (E). Each experiment was repeated twice. Data represent means SEM. *P < 0.05.
Rose et alCRH5 and EKKH5, but not in AB12 and AK7 (Figure 4B).
No differences in basal ROS levels (ie, no H2O2 added)
were found with increasing selenium levels in the MM
cell lines (Supplemental Figure S1). To determine if this1046difference in reducing capacity contributed to effects of
selenium on ERK activation and proliferation/mobility, we
used the reducing reagent NAC to eliminate differences in
redox status and compared all four MM cell lines. Westernajp.amjpathol.org - The American Journal of Pathology
Figure 5 Increasing dietary selenium in vivo promotes redox-
dependent tumor progression of CRH5, but not AB12, MM cells. Male
Balb/c mice were fed deﬁned diets containing low (0.08 ppm), medium
(0.25 ppm), and high (1.0 ppm) selenium as sodium selenite for 4 weeks,
and then 106 AB12 or CRH5 MM cells were injected s.c. and tumor volume
measurements were performed weekly. CRH5 also was injected into mice
maintained on drinking water containing 0.4 mmol/L NAC for the remainder
of the experiment. Mice were sacriﬁced when tumor volumes threatened the
health of the mice. Each experiment was repeated twice. Data represent
means  SEM. Means of each selenium group were compared at each time
point. N Z 5 per group. *P < 0.05.
Selenium and Mesothelioma Progressionblot analyses showed that treatment with NAC led to
equivalent pERK and pAKT levels in all four MM cell lines,
regardless of selenium levels (Figure 4C). NAC treatment
also resulted in equivalent proliferation and mobility in the
MM cell lines regardless of selenium levels (Figure 4D).
In Vivo CRH5 MM Tumor Progression Increases with
Increasing Dietary Selenium in a Manner that Depends
on Reducing Capacity
Balb/c mice were fed deﬁned diets containing 0.08, 0.25,
and 1.0 ppm selenium as sodium selenite for 4 weeks to
establish low, medium, and high selenium status, respec-
tively, as previously described.20 These mice then were
injected subcutaneously with the selenium-sensitive (CRH5)
and selenium-insensitive (AB12) MM cell lines. The mice
were maintained on the selenium diets throughout the study
and tumor volume was monitored over time. Similar to the
in vitro data described earlier, CRH5 MM tumor progres-
sion was increased with increasing dietary selenium levels,
whereas AB12 MM tumors showed no signiﬁcant effect
from increasing dietary selenium levels (Figure 5). NAC
treatment throughout the tumor measurements eliminated
the effects of dietary selenium on CRH5 tumor progression.
Thus, together with the in vitro data described earlier these
results suggest that certain MM tumors beneﬁt from
increasing selenium levels owing to increased reducing ca-
pacity exerted by this micronutrient.
Discussion
Selenium has been a topic of great interest in the ﬁeld of
cancer research, but the role of this essential micronutrient
in mesothelioma disease onset or progression has not been
elucidated fully. Because of its antioxidant and cancer-
cytotoxic properties, supernutritional levels of selenium are
thought to limit the pro-oxidant conditions that may initiate
carcinogenesis or fuel progression of established tumors.29
The role that higher selenium uptake plays in promoting
DNA damage repair is very different from the role selenium
and selenoproteins play in redox homeostasis in established,
proliferating cancer cells.19 Although our study does not
address MM carcinogenesis, our ﬁndings suggest that
higher selenium intake is not beneﬁcial for individuals with
established MM tumors. In fact, depending on the manner in
which increasing selenium is used for reducing capacity by
the MM cells comprising the tumor, selenium supplemen-
tation may even promote tumor progression.
Mesothelioma is a relatively rare form of cancer, but
signiﬁcant numbers of asbestos-exposed individuals in the
United States are still at risk of developing this deadly
disease and the incidence of mesothelioma is increasing in
many parts of the world.30,31 It is important to fully char-
acterize the relationship between dietary selenium and me-
sothelioma given that dietary selenium intake varies widely
compared with other micronutrients, with mean values of 40The American Journal of Pathology - ajp.amjpathol.orgmg per day in Europe and 93 mg per day (in women) to 134
mg per day (in men) in the United States.1 Furthermore, an
estimated 18% to 19% of adults in the United States use
supplements containing selenium32 and selenium fortiﬁca-
tion of foods is being pursued in many parts of the world to
boost suboptimal selenium levels in populations and
as a supernutritional means of nutritional cancer pre-
vention.33e35 The minimum selenium intake and super-
nutritional levels in rodents has been established to be 0.1
ppm and approximately 0.8 ppm, respectively.36 Thus, our
study was designed to include moderately low (0.08 ppm),
adequate (0.25 ppm), and supernutritional (1.0 ppm) levels
of selenium intake. Some rodent anticancer studies use diets
with 2.0 ppm selenium,37 which is likely to further increase
the levels of potential anticancer selenium metabolites.51047
Rose et alIf we had increased our mouse diets to 2.0 ppm we may
have found some toxic effects on the MM tumors, but given
that this level is 20-fold higher than the minimum intake and
the recommended 200 mg/day selenium-supplemented
levels in humans is fourfold higher than the minimum
intake,36 we chose a more realistic value of 1.0 ppm as a
supernutritional selenium diet for this study.
The speciﬁc mechanisms by which increased selenium
affects cancer cells are complex, with both selenoproteins
and selenium metabolites playing important roles.29 In fact,
selenoproteins themselves may play roles in both preventing
and promoting different types of cancer.13,38 Our ﬁndings
suggesting that some MM cells use increasing selenium to
increase reducing capacity reﬂected by increased GSH
stores are difﬁcult to explain through a simple model of
increased selenoprotein activity. There is no evidence to
date showing that selenoproteins directly contribute to
increased synthesis or stability of GSH, although other
studies have shown interactions between increasing sele-
nium and GSH levels.20,39 Comparing CRH5 with AB12
MM cell lines, both showed increased GPx1 activity with
increasing selenium uptake, but only CRH5 showed
increased GSH levels as well. This endowed CRH5 MM
cells with the ability to detoxify H2O2 more effectively with
increasing selenium, presumably through GPx1 activity.
Thus, GSH appears to be the limiting factor in mediating the
effects of increased selenium on redox status in MM cells
and this further affects the activation of pro-growth effector
molecules such as ERK. ERK is a crucial mitogen-activated
protein kinase that previously was identiﬁed as a ROS-
sensitive survival signaling factor.40 It also has been
shown that ERK activation is an essential step in the pro-
gression of mesothelioma tumors.41 Thus, we have estab-
lished an important link between selenium uptake, GSH
reserves, and ERK activation that may reﬂect a different
metabolism that is established in cancer cells arising from
inﬂammation driven by the original exposure to asbestos or
erionite. AKT was found to change with increasing sele-
nium levels only in CRH5, and this pro-growth factor may
reﬂect an additional signaling factor involved in the effects
of selenium on growth for some tumor cells, warranting
further investigation.
Interestingly, our ﬁndings suggest that MM cells, which
use bioavailable selenium more efﬁciently for higher
reducing capacity, may better adapt to the oxidative stress
associated with the dense environment of tumors. The data
showed that CRH5 and EKKH5 cells beneﬁtted most from
higher selenium conditions as cells approached conﬂuency.
Although our data do not deﬁnitively show a role for
reducing capacity or ERK activation in directly mediating
the effects of selenium on tumor cell growth, they do sup-
port the notion that redox tone and ERK activation are
linked to selenium levels and are involved in the prolifera-
tion of some MM cells. Our data are consistent with the
observations that the need of cancer cells to detoxify ROS
increases as the cell density increases.42 Whether MM cells1048use increasing selenium for increasing antioxidant capacity
may depend on their location within a tumor, availability to
the vasculature, or other factors. Overall, our data suggest
that increasing intake of selenium may not be beneﬁcial for
MM patients and provide important insight into the use of
this micronutrient by certain MM cells for increasing pro-
liferative capacity as cells approach high-density conditions.Acknowledgment
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